SJURVM schreef op 11 september 2016 15:56:
Investors in Gilead are growing impatient for the company to make a transformative acquisition, but could they be overlooking the undervalued partner they already own a stake in? Likewise, AbbVie might be having second thoughts over ending their first collaboration with the company, and an all ought buyout could rectify that mistake. I expect a buyout to command a minimum 50% premium, resulting in an $80+ share price.